PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 05/19/25

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson’s Disease and AATD programs in 1H 2026 and mid-2026, respectively;...

-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- ...

2025-05-08 18:48:19 ET Prime Medicine, Inc. (PRME) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.28%. The average open to low on the day of earnings was -4.65%. The average open to c...

2025-05-08 18:43:19 ET Prime Medicine, Inc. (PRME) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in PRME stock price following earnings has averaged ±2.06% , with a median of 2.13%. ...

2025-05-08 10:18:53 ET More on Prime Medicine Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 Cantor analysts call for RFK Jr. replacement following ousting of Marks at FDA How Peter Marks' FDA departure is impacting pharma, biotech st...

-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- ...

2025-04-25 10:51:29 ET Summary Initiate Hold on Prime Medicine due to pending Phase 1/2 CGD readout in 2025 and Wilson’s Disease IND filing in 2026, focusing on safety and mechanistic editing. Await six-month durability data in 2026 or clear non-dilutive funding before re-r...

2025-04-01 01:03:31 ET More on CRISPR Therapeutics, Moderna FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade) CRISPR Therapeutics Set To Reach Previous Heights Intel And Crispr: 2 'Bond-Like' Option Trades Yielding 13%+ How Peter Marks' F...

2025-03-31 12:37:32 ET More on Beam, CRISPR Therapeutics Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication CRISPR Therapeutics Set To Reach Previous Heights Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene ...

2025-03-20 18:48:00 ET News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (NASDAQ: PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence , in reaction, bullish inves...